Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis

Data are part of the DISCOVER 1 and 2 program, the first Phase 3 studies to evaluate a selective IL-23 p19 inhibitor in the treatment of psoriatic arthritis HORSHAM, Pa., June 14, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceut... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, psoriatic arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news